Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B


Yurdaydin C., Senturk H., Boron-Kaczmarska A., Raptopoulou-Gigi M., Batur Y., Goodman Z., et al.

41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, Avusturya, 26 - 30 Nisan 2006, cilt.44